Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Peter Biotherapeutics Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This case is assigned to 1 distinct examiner and 1 distinct art unit, representing a focused interaction with the patent office. This level of focus indicates that the company is currently pursuing a specific biological or pharmaceutical advancement. The pending office action is the only active case currently being prosecuted by the company.
The busiest examiner for the portfolio is LEITH, NANCY J, who handles 1 busiest examiner pending office action. With the pending action active, the company's current prosecution results are determined by the individual standards of this specific examiner. Practitioners should focus on the examiner's typical response patterns and allowance rates in the Biotechnology & Pharmaceuticals area. The success of the company's current patent application is tied to the feedback and requirements of this official. The progress of the 1 pending office action will serve as a benchmark for the company's future prosecution efforts in this technology sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEITH, NANCY J | 1 | 74.7% | +44.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001340 | GENETIC MODIFICATION | LEITH, NANCY J | 26d |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18001340 | GENETIC MODIFICATION | LEITH, NANCY J | 1636 | §103 | Non-Final OA | 26d | Pending | Dec 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial